Genotype Matters: Vagus Nerve Atrophy in GBA-Associated Parkinson’s Disease
Objective: The aim of this study is to compare the right and left vagus nerve (VN) cross-sectional area (CSA) and autonomic symptoms in patients with…Natural History of Sialidosis Type I: A Prospective Longitudinal Follow-Up Study of Clinical and Electrophysiological Markers
Objective: We performed a prospective analysis to determine the natural history as well as changes of electrophysiological markers in a cohort of Sialidosis type I.…GBA1 L444P mutation increases susceptibility to neuroinflammation and promotes pro-inflammatory immune responses
Objective: To determine whether the GBA1 L444P mutation increases susceptibility to neuroinflammation and alters immune responses during CNS inflammatory challenge. Background: Mutations in GBA1, which…GBA1 deficiency promotes tau and TDP-43 co-pathology
Objective: To determine whether mutations in the gene beta-glucocerebrosidase 1 (GBA1), the strongest genetic risk factor for PD, promote tau and TDP-43 co-pathology alongside Lewy…Analyzing the classification of 767 GBA1 variants to guide GBA1 PD risk prediction
Objective: To assess the consistency of GBA1 variant classification across large Parkinson’s disease (PD) and Gaucher disease (GD) cohorts and determine how variant-specific biochemical data…LRRK2 G2019S Drives Lysosomal Lipid Remodeling and Inflammation in Human iPSC-Derived Microglia
Objective: The aim of this study is to elucidate disease-related metabolic and inflammatory pathways driven by LRRK2 G2019S in human iPSC-derived microglia. Background: Parkinson’s Disease…NPC2 is an Allele-Specific Modifier of GBA1-Associated Parkinson’s Disease Risk
Objective: To identify rare variant modifiers of GBA1-associated Parkinson's disease (PD) penetrance among lysosomal storage disorder (LSD) genes. Background: GBA1 is the most common large-effect…Adult-Onset Incomplete Kufor-Rakeb Syndrome Presenting with Parkinsonism: A Case Report
Objective: To report two adult-onset cases of slowly progressive Parkinson’s disease (PD) carrying a heterozygous pathogenic ATP13A2 variant. Background: ATP13A2 (PARK9) encodes a P-type ATPase…Hyperkinetic Movement Disorder as the First Manifestation of Gaucher Disease Type 3
Objective: Gaucher disease, an autosomal recessive lysosomal storage disorder, is caused by a deficiency of the enzyme glucocerebrosidase. This results in the accumulation of glucosylceramide…Genome-wide Discovery of GBA1 Modifiers in Parkinsons Disease Carriers across Populations from the Global Parkinsons Genetics Program
Objective: To identify genetic risk modifiers for GBA1 risk variant carriers of European and African ancestry, we used data from GP2 (http://gp2.org/), the UK Biobank,…
- 1
- 2
- 3
- …
- 10
- Next Page »